ClinicalTrials.Veeva

Menu

Patient Reported Outcomes in Pulmonary Arterial Hypertension (PROPAH)

Viatris logo

Viatris

Status

Withdrawn

Conditions

Pulmonary Arterial Hypertension

Treatments

Other: Interview
Other: Questionnaire

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT01792622
A1481296

Details and patient eligibility

About

Develop a brief, new, patient reported outcome instrument that is valid for use in clinical practice and clinical trials.

Full description

This study will use the Clinical Impact Method to develop a patient reported outcome for use in patients with pulmonary arterial hypertension Clinical personnel at the study sites will approach and discuss possible participation in Phase I and II of the study with subjects from the existing pool of patients currently receiving usual and customary care at the site.

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Evidence of a personally signed and dated informed consent
  • Subjects aged >=18 who have documented PAH
  • Speak English
  • Subjects who provide written informed consent to participate in the study before being screened for the study.

Exclusion criteria

  • Patients with non-PAH Pulmonary Hypertension
  • Physical inability to complete the interview process
  • Subjects who are currently enrolled in an experimental drug study

Trial design

0 participants in 2 patient groups

Phase I Patient Interviews
Description:
Indepth interviews will be completed with approximately 15 patients.
Treatment:
Other: Interview
Phase II Patient Questionnaire
Description:
Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I
Treatment:
Other: Questionnaire

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems